ARMGO Pharma

About:

ARMGO Pharma develops small molecule therapeutics to treat debilitating cardiac, skeletal muscular, and neurological disorders.

Website: http://armgo.com

Top Investors: Forbion Capital Partners, Kurma Partners, Pontifax

Description:

ARMGO Pharma, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat debilitating cardiac, skeletal muscular, and neurological disorders. It offers rycals, which are calcium release channel stabilizers that act on ryanodine receptor/calcium release channel, a therapeutic target located on the sarcoplasmic/endoplasmic reticulum of the cell for treating chronic heart failure, cardiac arrythmias, and muscle disorders, as well as cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. The company was incorporated in 2004 and is based in Tarrytown, New York with an additional office in New York, New York.

Total Funding Amount:

$36M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Tarrytown, New York, United States

Founded Date:

2004-01-01

Contact Email:

info(AT)armgo.com

Founders:

Andrew Marks, Helen Wu

Number of Employees:

11-50

Last Funding Date:

2021-12-20

IPO Status:

Private

Industries:

© 2025 bioDAO.ai